Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches.
- 2023-09-26
- Review
- Microbiome research reports 2(4)
- Catherine O'Reilly
- Susan Mills
- Mary C Rea
- Aonghus Lavelle
- Subrata Ghosh
- Colin Hill
- R Paul Ross
- PubMed: 37849974
- DOI: 10.20517/mrr.2023.41
- Low evidence
For certain IBD therapeutics, the microbiome composition, particularly before treatment, may serve as a biomarker of therapeutic efficacy
- Effect
- Beneficial
- Effect size
- Small